Cutaneous castleman's disease responds to anti–interleukin-6 treatment

Castleman's disease is uncommon, and cutaneous involvement is even rarer. We report a 42-year-old Asian woman with the multicentric plasma cell variant of Castleman's disease limited to her skin. The literature suggests that Castleman's disease is driven by interleukin-6 (IL-6). Based on these data, we hypothesized that suppression of IL-6 would have a salutary effect. Therefore, our patient was treated with CNTO328, a chimeric murine anti-human IL-6 antibody. She has shown a remarkable, ongoing response to this treatment, with almost complete clearing of her skin lesions after six doses. [Mol Cancer Ther 2007;6(9):2386–90]

[1]  R. Kurzrock,et al.  CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies. , 2006 .

[2]  M. Landthaler,et al.  Targeting T Cells to Hit B Cells: Successful Treatment of Cutaneous Plasmacytosis with Topical Pimecrolimus , 2006, Dermatology.

[3]  A. Jayaraman,et al.  Cutaneous Plasmacytosis: A Report of Five Cases with Immunohistochemical Evaluation for HHV-8 Expression , 2006, The American Journal of dermatopathology.

[4]  E. Jordá,et al.  Cutaneous plasmacytosis associated with lung and anal carcinomas , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  H. Tseng,et al.  Primary cutaneous plasmacytosis successfully treated with topical photodynamic therapy. , 2005, Acta dermato-venereologica.

[6]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[7]  N. Munshi,et al.  Multicentric plasma cell variant of Castleman's disease with cutaneous involvement , 2004, Journal of cutaneous pathology.

[8]  K. Yoshikawa,et al.  Treatment of facial lesion of cutaneous plasmacytosis with tacrolimus ointment. , 2003, Journal of the American Academy of Dermatology.

[9]  P. Mclaughlin,et al.  Cutaneous and systemic plasmacytosis in a patient of Asian descent living in the United States. , 2002, The American Journal of dermatopathology.

[10]  M. Aricò,et al.  Primary cutaneous plasmacytosis in a child. Is this a new entity? , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  R. Kurzrock,et al.  Cytokine deregulation in cancer. , 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  B. Vion,et al.  Cutaneous Plasmacytosis: An Unusual Presentation Sharing Features with POEMS Syndrome? , 2001, Dermatology.

[13]  M. Komine,et al.  Plasmacytosis: systemic or cutaneous, are they distinct? , 2000, Acta dermato-venereologica.

[14]  M. Rico,et al.  Systemic plasmacytosis with cutaneous manifestations in a white man: successful therapy with cyclophosphamide/prednisone. , 1998, Journal of the American Academy of Dermatology.

[15]  K. Nishioka,et al.  Increased plasma interleukin‐6 in cutaneous plasmacytoma: the effect of intralesional steroid therapy , 1997, The British journal of dermatology.

[16]  H. Shimizu,et al.  Is cutaneous plasmacytosis a distinct clinical entity? , 1997, Journal of the American Academy of Dermatology.

[17]  M. Fujita,et al.  Successful treatment with topical PUVA of nodular cutaneous plasmacytosis associated with alopecia of the scalp , 1996, Clinical and experimental dermatology.

[18]  D. Mullins,et al.  Subcutaneous Castleman's disease of the wrist. , 1995, The American Journal of dermatopathology.

[19]  Y. Kubota,et al.  Skin involvement in giant lymph node hyperplasia (Castleman's disease). , 1993, Journal of the American Academy of Dermatology.

[20]  T. Matsui,et al.  Systemic and cutaneous plasmacytosis with multiple skin lesions and polyclonal hypergammaglobulinaemia: significant serum interleukin‐6 levels , 1992, The British journal of dermatology.

[21]  J. Diebold,et al.  Interleukin-6 gene expression in Castleman's disease. , 1991, Blood.

[22]  A. Nienhuis,et al.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. , 1990, The Journal of clinical investigation.

[23]  U. Nydegger,et al.  [Cutaneous plasmacytosis and polyclonal cryo-immunoglobulinemia]. , 1978, Schweizerische medizinische Wochenschrift.

[24]  B. Castleman,et al.  Localized mediastinal lymph‐node hyperplasia resembling thymoma , 1956, Cancer.

[25]  K. Smith,et al.  Extranodal multicentric Castleman's disease with cutaneous involvement. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[26]  Smith Kj,et al.  EXTRANODAL MULTICENTRIC CASTLEMAN'S DISEASE WITH CUTANEOUS INVOLVEMENT , 1998 .

[27]  K. Nishioka,et al.  Intralesional steroid-therapy-induced reduction of plasma interleukin-6 and improvement of cutaneous plasmacytosis. , 1995, Dermatology.

[28]  T. Saida,et al.  Primary cutaneous plasmacytosis: report of three cases and review of the literature. , 1994, Dermatology.